Riskpilot← Back to searchSign inGet full accessBIOCON AS
ASActiveOrg 925975885Bernt Lies veg 8B, 7024 TrondheimOther business support service activities n.e.c. · NACE 8299Est. 20200 employees
Revenue 2024
NOK 0
EBITDA margin
—
-85% vs 2023
Equity ratio
-18.2%
Financial strength
Net profit 2024
NOK -13K
-167% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -17K | -85% |
| Net profit | NOK -13K | -167% |
| Total assets | NOK 17K | -85% |
| Equity | NOK -3K | -131% |
| Employees | 0 | — |
Legal name
BIOCON AS
Org number
925975885
Legal form
Aksjeselskap
NACE code
8299 · Other business support service activities n.e.c.
Founded
17. november 2020
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder eller styrets leder hver for seg.
Company purpose
Konsulentvirksomhet innen kartlegging, bekjemping og kompetanseutvikling vedrørende fremmedarter, og annet som naturlig faller sammen med dette.
Address
Bernt Lies veg 8B, 7024 Trondheim
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 307 | 9 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −1 | −69 | 61 | −9 | −17 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −1 | −69 | 61 | −9 | −17 |
| Net financials | 0 | 0 | 0 | 0 | −0 |
| Profit before tax | −1 | −69 | 61 | −9 | −17 |
| Tax | −0 | −0 | −0 | −4 | −4 |
| Net profit | −1 | −69 | 61 | −5 | −13 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 123 | 54 | 115 | 110 | 17 |
| Equity | 23 | −46 | 15 | 10 | −3 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 100 | 100 | 100 | 100 | 20 |
| Total debt | 100 | 100 | 100 | 100 | 20 |
EBITDA margin
-1653100.0%
This company
15.8%
Market median
-10462758% vs market
20202024
Equity ratio
-18.2%
This company
38.2%
Market median
-148% vs market
20202024
Return on equity
-1290100.0%
This company
18.4%
Market median
-7011513% vs market
20202024
Net profit margin
-1290100.0%
This company
8.1%
Market median
-15927260% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
6.48×
This company
0.62×
Market median
-945% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-10-26 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AE Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 30% | 30% | 2022 | |
| Company | 30% | 30% | 2022 | |
| Individual | 20% | 20% | 2022 | |
| Company | 20% | 20% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIOCON AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Amanda Engberg Andersen | Chief Executive Officer | 0 companies |
| Gunnar Kristiansen | Board of Directors | 0 companies |
| Geir Frode Langelo | Chairman | 0 companies |